DxTerity Diagnostics Begins Enrollment in the ELEVATE Clinical Study for Lupus
May 27, 2022 LOS ANGELES, May 27, 2022 /PRNewswire/ — DxTerity Diagnostics today announced the opening of enrollment in ELEVATE (Empower Lupus Erythematous Patients Via Allowing RemoTe Evaluation), a new observational clinical study for patients with Systemic Lupus Erythematosus (SLE or lupus). The study opening aligns with Lupus Awareness Month (May) and efforts to advance precision medicine and improve the lives of patients […]
DxTerity Diagnostics Announces the Launch of IFN-1 Test for Lupus
Jun 09, 2022 DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus. DxTerity’s test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE […]
A Digital Assay to Streamline PD-L1 IHC: Published in Scientific Reports
Jun 14, 2022 Flagship Biosciences, Inc., today announced the publication of a paper describing validation of a novel digital spatial biology assay in Scientific Reports. The assay, Tissue Insight (TI) 22C3 NSCLC, surpasses manual scoring in PD-L1 positive tumor samples. Modern cancer immunotherapy for non-small cell lung cancer (NSCLC) utilizes programmed death-ligand 1 (PD-L1) checkpoint […]
YDS Pharmatech Helps Uncover a Novel Viral Recognition Pathway: Published in Nature Chemical Biology
Aug 18, 2022 YDS Pharmatech announced the publication of a paper revealing a novel human viral recognition mechanism in Nature Chemical Biology today. The publication was co-authored by Xing Che, Ph.D., founder and CEO of YDS Pharmatech, and by researchers at Tianjin Medical University led by Prof. Heng Zhang. The company helped reveal a new viral protein […]
